Clinical utility of pharmacogenomics in the management of hepatitis C

References

• WangLMcLeodHLWeinshilboumRLGenomics and drug responseN Engl J Med2011364121144115321428770
   PubMed Web of Science ®Google Scholar
• WeinshilboumRMWangLPharmacogenetics and pharmacogenomics: development, science and translationAnnu Rev Genomics Hum Genet2006722324516948615
   PubMed Web of Science ®Google Scholar
• International HapMap ConsortiumA haplotype map of the human genomeNature200543770631299132016255080
   PubMed Web of Science ®Google Scholar
• ThurszMYeeLKhakooSUnderstanding the host genetics of chronic hepatitis B and CSemin Liver Dis201131211512721538279
   PubMed Web of Science ®Google Scholar
• SuppiahVMoldovanMAhlenstielGInterleukin 28B is associated with response to hepatitis C interferon-alpha and ribavirin therapyNat Genet200941101100110419749758
   PubMed Web of Science ®Google Scholar
• TanakaYNishidaNSugiyamaMGenome-wide association of interleukin 28B with response to interferon alpha and ribavirin therapy for chronic hepatitis CNat Genet200941101105110919749757
   PubMed Web of Science ®Google Scholar
• GeDFellayJThompsonAJGenetic variation in interleukin 28B predicts hepatitis C treatment-induced viral clearanceNature2009461726239940119684573
   PubMed Web of Science ®Google Scholar
• RauchAKutalikZDescombesPSwiss Hepatitis C Cohort Study and Swiss HIV Cohort StudyGenetic variation in interleukin 28B is associated with chronic hepatitis C and treatment failure: genome-wide association studyGastroenterology201013841338134520060832
   PubMed Web of Science ®Google Scholar
• ThomasDLThioCLMartinMPGenetic variation in IL28B and spontaneous clearance of hepatitis C virusNature2009461726579880119759533
   PubMed Web of Science ®Google Scholar
• RedalMBellosoWHGarfiIScibonaPIsolabellaSPharmacogenomics in gastroenterologySanoudouDClinical Applications of PharmacogeneticsRijeka, CroatiaIn Tech2012
   Google Scholar
• BellosoWHRedalMAPharmacogenomics and the path towards personalized medicineMedicina (B Aires)201070326527420529779
   PubMed Web of Science ®Google Scholar
• ChooQLKuoGWeinerAJOverbyLRBradleyDWHoughtonMIsolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genomeScience198924449023593622523562
   PubMed Web of Science ®Google Scholar
• MühlbergerNSchwarzerRLettmeierBSroczynskiGZeuzemSSiebertUHCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortalityBMC Public Health200993419161623
   PubMed Web of Science ®Google Scholar
• HadziyannisSJSetteHJrMorganTRPEGASYS International Study GroupPeginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin doseAnn Intern Med2004140534635514996676
   PubMed Web of Science ®Google Scholar
• FowellAJNashKLTelaprevir: a new hope in the treatment of chronic hepatitis C?Adv Ther201027851252220652658
   PubMed Web of Science ®Google Scholar
• ThomasDLAstemborskiJRaiRMThe natural history of hepatitis C virus infection: host, viral, and environmental factorsJAMA2000284445045610904508
   PubMed Web of Science ®Google Scholar
• AborsangayaKBDembinskiIKhatkarSAlphonseMPNickersonPRempelJDImpact of aboriginal ethnicity on HCV core-induced IL-10 synthesis: interaction with IL-10 gene polymorphismsHepatology200745362363017326156
   PubMed Web of Science ®Google Scholar
• TrinksJHulaniukMLCaputoMDistribution of genetic polymorphisms associated to hepatitis C virus (HCV) antiviral response in a multiethnic and admixed populationPharmacogenomics J5202014 [Epub ahead of print.]
   Web of Science ®Google Scholar
• MangiaAThompsonAJSantoroRAn IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic responseGastroenterology2010139382182720621700
   PubMed Web of Science ®Google Scholar
• SarrazinCSusserSDoehringAImportance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patientsJ Hepatol201154341542121112657
   PubMed Web of Science ®Google Scholar
• ScherzerTMStättermayerAFStrasserMImpact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirinHepatology20115451518152622006276
   PubMed Web of Science ®Google Scholar
• Montes-CanoMAGarcía-LozanoJRAbad-MolinaCInterleukin-28B genetic variants and hepatitis virus infection by different viral genotypesHepatology2010521333720578254
   PubMed Web of Science ®Google Scholar
• RallonNINaggieSBenitoJMAssociation of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patientsAIDS2010248F23F2920389235
   PubMed Web of Science ®Google Scholar
• YuMLHuangCFHuangJFRole of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patientsHepatology201153171321254157
   PubMed Web of Science ®Google Scholar
• MangiaAThompsonAJSantoroRLimited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoringHepatology201154377278021626525
   PubMed Web of Science ®Google Scholar
• ThompsonAJMuirAJSulkowskiMSInterleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virusGastroenterology2010139112012920399780
   PubMed Web of Science ®Google Scholar
• ChayamaKTsubotaAKobayashiMPretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infectionHepatology19972537457499049229
   PubMed Web of Science ®Google Scholar
• HayesCNKobayashiMAkutaNHCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapyGut201160226126721068134
   PubMed Web of Science ®Google Scholar
• LindhMLaggingMArnholmBIL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1J Viral Hepat2011187e325e33121692944
   PubMed Web of Science ®Google Scholar
• OchiHMaekawaTAbeHIL-28B predicts response to chronic hepatitis C therapy – fine-mapping and replication study in Asian populationsJ Gen Virol201192Pt 51071108121228123
   PubMed Web of Science ®Google Scholar
• StättermayerAFStauberRHoferHImpact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis CClin Gastroenterol Hepatol20119434435020728570
   PubMed Web of Science ®Google Scholar
• LinCYChenJYLinTNIL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infectionPLoS One201163e1832221479134
   PubMed Web of Science ®Google Scholar
• FukuharaTTaketomiAMotomuraTVariants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis CGastroenterology201013951577158520708617
   PubMed Web of Science ®Google Scholar
• CharltonMRThompsonAVeldtBJInterleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infectionHepatology201153131732421254179
   PubMed Web of Science ®Google Scholar
• Coto-LlerenaMPérez-del-PulgarSCrespoGDonor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantationAm J Transplant20111151051105721466653
   PubMed Web of Science ®Google Scholar
• O’BrienTRProkunina-OlssonLDonnellyRPIFN-λ4: the paradoxical new member of the interferon lambda familyJ Interferon Cytokine Res4302014 [Epub ahead of print.]
   Web of Science ®Google Scholar
• YoshimotoKKishidaTNakanoHInterleukin-28B acts synergistically with cisplatin to suppress the growth of head and neck squamous cell carcinomaJ Immunother201134213914821304406
   PubMedGoogle Scholar
• MorrowMPYanJPankhongPIL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaquesMol Ther20101891714172320571540
   PubMed Web of Science ®Google Scholar
• KotenkoSVGallagherGBaurinVVIFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complexNat Immunol200341697712483210
   PubMed Web of Science ®Google Scholar
• ZhangLJilgNShaoRXIL28B inhibits hepatitis C virus replication through the JAK-STAT pathwayJ Hepatol201155228929821147189
   PubMed Web of Science ®Google Scholar
• ZhouZHammingOJAnkNPaludanSRNielsenALHartmannRType III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinasesJ Virol200781147749775817507495
   PubMed Web of Science ®Google Scholar
• RehermannBHepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistenceJ Clin Invest200911971745175419587449
   PubMed Web of Science ®Google Scholar
• KawaiTTakahashiKSatoSIPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon inductionNat Immunol200561098198816127453
   PubMed Web of Science ®Google Scholar
• XuLGWangYYHanKJLiLYZhaiZShuHBVISA is an adapter protein required for virus-triggered IFN-beta signalingMol Cell200519672774016153868
   PubMed Web of Science ®Google Scholar
• SethRBSunLEaCKChenZJIdentification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3Cell2005122566968216125763
   PubMed Web of Science ®Google Scholar
• HayesCNImamuraMAikataHChayamaKGenetics of IL28B and HCV – response to infection and treatmentNat Rev Gastroenterol Hepatol20129740641722641049
   PubMed Web of Science ®Google Scholar
• AsahinaYTsuchiyaKMuraokaMAssociation of gene expression involving innate immunity and genetic variation in IL28B with antiviral responseHepatology2012551202921898478
   PubMed Web of Science ®Google Scholar
• Prokunina-OlssonLMuchmoreBTangWA variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virusNat Genet201345216417123291588
   PubMed Web of Science ®Google Scholar
• BibertSRogerTCalandraTIL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance predictionJ Exp Med201321061109111623712427
   PubMed Web of Science ®Google Scholar
• SorianoVPovedaEVispoELabargaPRallónNBarreiroPPharmacogenetics of hepatitis CJ Antimicrob Chemother201267352352922194301
   PubMed Web of Science ®Google Scholar
• De FranceschiLFattovichGTurriniHemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damageHepatology2000314997100410733558
   PubMed Web of Science ®Google Scholar
• FellayJThompsonAJGeDITPA gene variants protect against anemia in patients treated for chronic hepatitis CNature2010464728740540820173735
   PubMed Web of Science ®Google Scholar
• BierauJLindhoutMBakkerJAPharmacogenetic significance of inosine triphosphatasePharmacogenomics2007891221122817924837
   PubMed Web of Science ®Google Scholar
• StoccoGCheokMHCrewsKRGenetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemiaClin Pharmacol Ther200985216417218685564
   PubMed Web of Science ®Google Scholar
• ThompsonAFellayJPatelKVariants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reductionGastroenterology201013941181118920547162
   PubMed Web of Science ®Google Scholar
• OgawaEFurusyoNNakamutaMClinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapyJ Hepatol201359466767423707372
   PubMed Web of Science ®Google Scholar
• ThompsonAJClarkPJSinghAGenome-wide association study of interferon-related cytopenia in chronic hepatitis C patientsJ Hepatol201256231331921703177
   PubMed Web of Science ®Google Scholar
• ClarkPJAghemoADegasperiEInosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapyJ Viral Hepat2013201285886624304455
   PubMed Web of Science ®Google Scholar
• RembeckKWaldenströmJHellstrandKVariants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3Hepatology20145962131213924519039
   PubMed Web of Science ®Google Scholar
• AfdhalNMcHutchisonJZeuzemSHepatitis C pharmacogenetics: state of the art in 2010Hepatology201153133634521254181
   PubMed Web of Science ®Google Scholar
• HeningBJHellierSFrodshamAJAssociation of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infectionGenes Immun20023635936712209363
   PubMed Web of Science ®Google Scholar
• PinedaJACaruzADi LelloFALow-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patientsAIDS201125111415142021572301
   PubMed Web of Science ®Google Scholar
• PinedaJACaruzARiveroAPrediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virusClin Infect Dis201051778879520804372
   PubMed Web of Science ®Google Scholar
• PettaSCammàCScazzoneCLow vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis CHepatology20105141158116720162613
   PubMed Web of Science ®Google Scholar
• LangeCMBojungaJRamos-LopezEVitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapyJ Hepatol201154588789321145801
   PubMed Web of Science ®Google Scholar
• UitterlindenAGFangYVan MeursJBPolsHAVan LeeuwenJPGenetics and biology of vitamin D receptor polymorphismsGene2004338214315615315818
   PubMed Web of Science ®Google Scholar
• FosterGRGoldinRDThomasHCChronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosisHepatology19982712092129425939
   PubMed Web of Science ®Google Scholar
• DalgardOEgelandASkaugKVilimasKSteenTHealth-related quality of life in active injecting drug users with and without chronic hepatitis C virus infectionHepatology2004391748014752825
   PubMed Web of Science ®Google Scholar
• RifaiMAGleasonOCSabouniDPsychiatric care of the patient with hepatitis C: a review of the literaturePrim Care Companion J Clin Psychiatry2010126PCC.09r0087721494349
   PubMedGoogle Scholar
• McHutchisonJGWareJEJrBaylissMSHepatitis Interventional Therapy GroupThe effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivityJ Hepatol200134114014711211891
   PubMed Web of Science ®Google Scholar
• WareJEJrBaylissMSMannocchiaMDavisGLHealth-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy GroupHepatology199930255055510421667
   PubMed Web of Science ®Google Scholar
• BernsteinDKleinmanLBarkerCMRevickiDAGreenJRelationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patientsHepatology200235370470811870387
   PubMed Web of Science ®Google Scholar
• RifaiMAMolesJKShortDDHepatitis C treatment eligibility and outcomes among patients with psychiatric illnessPsychiatr Serv200657457057216603757
   PubMed Web of Science ®Google Scholar
• MatsushitaHIkedaFIwasakiYAssessment of health-related quality of life and how it predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis CJ Gastroenterol Hepatol201429233734323869873
   PubMed Web of Science ®Google Scholar
• LiuSCiprianoLEHolodniyMOwensDKGoldhaber-FiebertJDNew protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysisAnn Intern Med2012156427929022351713
   PubMed Web of Science ®Google Scholar
• ThompsonAJMcHutchisonJGWill IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus?Hepatology201256137338122511355
   PubMed Web of Science ®Google Scholar